Osiris Therapeutics 8-K 2012
WASHINGTON, D.C. 20549
Date of Report (Date of earliest event reported): October 22, 2012
OSIRIS THERAPEUTICS, INC.
(Exact Name of Registrant as Specified in Charter)
Registrants telephone number, including area code: (443) 545 - 1800
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
ITEM 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
On October 22, 2012, Lode Debrabandere, Ph.D. was promoted to serve as Chief Operating Officer of Osiris Therapeutics, Inc. (the Company). Dr. Debrabandere will report directly to C. Randal Mills, Ph.D., President and Chief Executive Officer. Until his promotion, Dr. Debrabandere served as Senior Vice President for Therapeutics for the Company. To date, there has been no change to the employment agreement between Dr. Debrabandere and the Company on account of the promotion.
Biographical information for Dr. Debrabandere can be found in the Companys Annual Report on Form 10-K for the year ended December 31, 2011 and Proxy Statement filed with the Securities and Exchange Commission on April 27, 2012.
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.